Exabis Library
Welcome to the e-CCO Library!
P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P533: Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P533: Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P533: Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P534: Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P534: Illness perception in IBD patients: a prospective study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P534: Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in Russia: results of the EXPLORE study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factors
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P535: Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn’s disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P535: COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P535: Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P535: Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM